Login / Signup

The SYK inhibitor: a novel agent for improved outcomes in relapsed/refractory diffuse large B-cell lymphoma.

Reem KarmaliFrédérique St-PierreLeo I Gordon
Published in: Future oncology (London, England) (2023)
Keyphrases
  • diffuse large b cell lymphoma
  • epstein barr virus
  • tyrosine kinase
  • type diabetes
  • skeletal muscle
  • adipose tissue
  • hodgkin lymphoma
  • glycemic control